{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:36:12Z","timestamp":1787016972017,"version":"build-2736575974"},"reference-count":36,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb","award":["CA209-9MJ"],"award-info":[{"award-number":["CA209-9MJ"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,4,15]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Grade group 5 (GG5) prostate cancer (PCa) carries a less favorable prognosis after standard-of-care (SOC) therapy, necessitating novel therapeutic approaches. High-dose rate brachytherapy (HDRBT) and androgen deprivation therapy (ADT) may modulate immune response in GG5 PCa, particularly in tumors with increased immune content. This study evaluated whether the addition of nivolumab to SOC was associated with improved disease control in patients with high-volume GG5 PCa, including those with oligometastatic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this non-randomized phase II trial, 31 patients with localized or oligometastatic GG5 PCa and &gt;30% positive biopsy cores were evaluated between September 2018 and April 2021. Patients received four doses of nivolumab (240\u2009mg every 2\u2009weeks) beginning 4\u2009weeks prior to HDRBT, alongside ADT, HDRBT, and external beam radiation. The primary endpoint was to evaluate whether the 2-year freedom from biochemical recurrence (FFBR) rate would exceed a prespecified historical control rate of 75%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 31 patients, the median follow-up was 38.8 months (IQR 31.0\u201346.5 months). The addition of nivolumab to SOC RT with ADT was associated with a 2-year FFBR rate of 90.3% (95% CI 74.3% to 98.0%) (median FFBR not reached), exceeding the prespecified historical control rate of 75% (one-sided p value from binomial test=0.024). Definitive and probable nivolumab-related toxicity included 6.3% acute grade 2 and 6.3%\u2009acute grade 3 adverse events (AEs), with no grade 4+ AEs observed. A higher Decipher immunosuppression score at diagnosis correlated with early pathologic response (p=0.005) and was independently associated with time to metastatic failure (p=0.044).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nivolumab combined with SOC was associated with encouraging FFBR in this high-risk GG5 PCa population and may represent a promising therapeutic intensification strategy. The Decipher immunosuppression score may serve as a predictive biomarker for response. These findings warrant further investigation in randomized trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013906","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:15:19Z","timestamp":1777914919000},"page":"e013906","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03543189","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"John Michael","family":"Bryant","sequence":"first","affiliation":[{"name":"Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"},{"name":"Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sandoval","sequence":"additional","affiliation":[{"name":"Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Putney","sequence":"additional","affiliation":[{"name":"Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purvish","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther N","family":"Katende","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Fink","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Mahrukh","family":"Naqvi","sequence":"additional","affiliation":[{"name":"Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngchul","family":"Kim","sequence":"additional","affiliation":[{"name":"Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Yin","sequence":"additional","affiliation":[{"name":"Biostatistics and Bioinformatics, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Y","family":"Park","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Serna","sequence":"additional","affiliation":[{"name":"Anatomic Pathology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nghi","family":"Lam","sequence":"additional","affiliation":[{"name":"Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pow-Sang","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Poch","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J","family":"Manley","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Naghavi","sequence":"additional","affiliation":[{"name":"Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Torres-Roca","sequence":"additional","affiliation":[{"name":"Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Daniel","family":"Grass","sequence":"additional","affiliation":[{"name":"Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjune","family":"Kim","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Mayo Clinic Alix College of Medicine & Health Sciences, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kujtim","family":"Latifi","sequence":"additional","affiliation":[{"name":"Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Hunt","sequence":"additional","affiliation":[{"name":"Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Johnstone","sequence":"additional","affiliation":[{"name":"Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasreman","family":"Dhillon","sequence":"additional","affiliation":[{"name":"Anatomic Pathology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo C","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Immuno-Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Jain","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine\/NewYork-Presbyterian Hospital, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9055-3538","authenticated-orcid":false,"given":"Kosj","family":"Yamoah","sequence":"additional","affiliation":[{"name":"Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026050410151000000_14.5.e013906.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70223-0"},{"key":"2026050410151000000_14.5.e013906.2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0063"},{"key":"2026050410151000000_14.5.e013906.3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1200\/JCO.2018.36.6_suppl.130","article-title":"Which patients with localized prostate cancer account for the greatest proportion of prostate cancer deaths?","volume":"36","author":"Nezolosky","year":"2018","journal-title":"JCO"},{"key":"2026050410151000000_14.5.e013906.4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eururo.2018.08.033","article-title":"Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer","volume":"75","author":"Yang","year":"2019","journal-title":"Eur Urol"},{"key":"2026050410151000000_14.5.e013906.5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/jjco\/hyad178","article-title":"Outcomes in patients with high- and very high-risk localized prostate cancer treated with definitive IMRT and long-term hormone therapy","volume":"54","author":"Kawamura","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2026050410151000000_14.5.e013906.6","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00066-019-01476-z","article-title":"Treatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapy\u202f: TROD 09-001 multi-institutional study","volume":"195","author":"Ozyigit","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"2026050410151000000_14.5.e013906.7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.radonc.2019.08.020","article-title":"Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902","volume":"141","author":"Hamstra","year":"2019","journal-title":"Radiother Oncol"},{"key":"2026050410151000000_14.5.e013906.8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155484","article-title":"Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review","volume":"21","author":"Kim","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026050410151000000_14.5.e013906.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70189-5"},{"key":"2026050410151000000_14.5.e013906.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.07.032"},{"key":"2026050410151000000_14.5.e013906.11","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920936084"},{"key":"2026050410151000000_14.5.e013906.12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk0642","article-title":"Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade","volume":"16","author":"Jagodinsky","year":"2024","journal-title":"Sci Transl Med"},{"key":"2026050410151000000_14.5.e013906.13","doi-asserted-by":"publisher","DOI":"10.2741\/2441"},{"key":"2026050410151000000_14.5.e013906.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.251140998"},{"key":"2026050410151000000_14.5.e013906.15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41391-020-0254-y","article-title":"Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis","volume":"24","author":"Yuan","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026050410151000000_14.5.e013906.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.11.026"},{"key":"2026050410151000000_14.5.e013906.17","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050"},{"key":"2026050410151000000_14.5.e013906.18","doi-asserted-by":"publisher","DOI":"10.1118\/1.598373"},{"key":"2026050410151000000_14.5.e013906.19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000193","article-title":"African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome","volume":"202","author":"Echevarria","year":"2019","journal-title":"J Urol"},{"key":"2026050410151000000_14.5.e013906.20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85902","article-title":"Claudin-low bladder tumors are immune infiltrated and actively immune suppressed","volume":"1","author":"Kardos","year":"2016","journal-title":"JCI Insight"},{"key":"2026050410151000000_14.5.e013906.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.075"},{"key":"2026050410151000000_14.5.e013906.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0587"},{"key":"2026050410151000000_14.5.e013906.23","first-page":"21","article-title":"Does brachytherapy boost improve survival outcomes in Gleason Grade Group 5 patients treated with external beam radiotherapy and androgen deprivation therapy? A systematic review and meta-analysis","volume":"38","author":"Tang","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"2026050410151000000_14.5.e013906.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2015.02.389"},{"key":"2026050410151000000_14.5.e013906.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.07.011"},{"key":"2026050410151000000_14.5.e013906.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2824"},{"key":"2026050410151000000_14.5.e013906.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02437-5"},{"key":"2026050410151000000_14.5.e013906.28","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"key":"2026050410151000000_14.5.e013906.29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","article-title":"Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology\/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials","volume":"116","author":"Nguyen","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026050410151000000_14.5.e013906.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.05.042"},{"key":"2026050410151000000_14.5.e013906.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.017"},{"key":"2026050410151000000_14.5.e013906.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64280-2"},{"key":"2026050410151000000_14.5.e013906.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.01.007"},{"key":"2026050410151000000_14.5.e013906.34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.urolonc.2020.05.023","article-title":"Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer","volume":"38","author":"Yang","year":"2020","journal-title":"Urol Oncol"},{"key":"2026050410151000000_14.5.e013906.35","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.clon.2023.03.018","article-title":"Multi-Institutional Clinical Outcomes of Biopsy Gleason Grade Group 5 Prostate Cancers Treated With Contemporary High-Dose Radiation and Long-Term Androgen Deprivation Therapy","volume":"35","author":"Chilukuri","year":"2023","journal-title":"Clin Oncol"},{"key":"2026050410151000000_14.5.e013906.36","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:15:22Z","timestamp":1777914922000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2025-013906"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013906","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}